ERBB2 and non-small cell lung carcinoma: For example, in oncogene driver mutated subsets of NSCLC cells like EGFR, HER2 or ALK, ROS, RET and MET fusions, limited benefit was obtained from ICB, despite enhanced PD-L1 expression, possibly because of downregulation of the TMB and tumor-infiltrated lymphocytes (TILs) [14,22].